VERZENIO (abemaciclib) is indicated in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. b. as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. Active ingredients in VERZENIO are: abemaciclib. Inactive ingredients in VERZENIO are: microcrystalline cellulose 102, microcrystalline cellulose 101, lactose monohydrate, croscarmellose sodium, sodium stearyl fumarate, silicon dioxide VERZENIO(abemaciclib) tablets should be administered under the supervision of a qualified physician experienced in the uses of cancer chemotherapeutic agents.

Where can I buy Verzenio?

Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its presence PAN India with over 20 years of domain experience.

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Verzenio (abemaciclib) tablets on prescription and Import License in Patient's Name only.

For Verzenio or (abemaciclib) tablets price in India.
Please contact +91 9811747774 or neeraj@indianpharmanetwork.co.in
Verzenio (abemaciclib) tablets

Get In Touch

Facilitator under Patient Assistance Programs In India

For Indian Patients, doctors and hospitals Verzenio (abemaciclib) tablets can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Dosage Forms and Strengths

Tablets: 50 mg, 100 mg, 150 mg, and 200 mg.

ReadMore

FDA Approval Summary

Lilly Receives Additional FDA Approval for Verzenio™ (abemaciclib), as Initial Treatment for Advanced Breast Cancer
Feb 26, 2018,

ReadMore